Rigel Pharmaceuticals (RIGL) Fundamental Analysis: Revenue, Earnings & Valuation

4.75 / 10

Netural

Rigel's fundamental assessment is average (4.8/10). Key positives include a healthy 84.48% year-over-year revenue growth and a solid interest-coverage ratio of 32.13%, which support the company's ability to service debt. However, a high days-sales-outstanding of 52.65 indicates slower receivable collection, and several valuation metrics (e.g., PB-ROE, Asset-MV) fall in less attractive quartiles. Overall, the fundamentals are stable but not compelling, warranting a neutral rating.

Analysis Checks(10/10)

Revenue-MV

Value-0.12

Score2/3

Weight13.91%

1M Return7.73%

Total operating revenue (YoY growth rate %)

Value84.48

Score2/3

Weight1.52%

1M Return1.11%

Days sales outstanding

Value52.65

Score2/3

Weight1.54%

1M Return1.10%

Profit-MV

Value2.08

Score3/3

Weight17.09%

1M Return9.28%

Net income-Revenue

Value0.89

Score3/3

Weight16.87%

1M Return9.29%

PB-ROE

Value1.05

Score2/3

Weight17.68%

1M Return9.14%

Interest coverage ratio (EBIT / Interest expense) (%)

Value32.14

Score2/3

Weight-1.42%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value84.48

Score2/3

Weight0.59%

1M Return0.43%

Asset-MV

Value-0.50

Score2/3

Weight18.28%

1M Return10.15%

Cash-MV

Value0.26

Score2/3

Weight13.94%

1M Return8.41%

Is RIGL fundamentally strong?

RIGL scores 4.75/10 on fundamentals and holds a Fair valuation at present. Backed by its 163.71% ROE, 40.17% net margin, 5.47 P/E ratio, 5.27 P/B ratio, and 2652.17% earnings growth, these metrics solidify its Netural investment rating.